Glioblastoma Clinical Trial Pipeline Analysis: 150+ Key Companies Advancing the Future of Glioblastoma Therapeutics | DelveInsight

DelveInsight's Glioblastoma Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline glioblastoma therapies in different stages of clinical development. Major pharmaceutical and biotech companies are actively working to advance the glioblastoma pipeline landscape and improve future treatment possibilities for this highly aggressive brain cancer.

Key takeaways from the Glioblastoma Clinical Trial Landscape Report
• DelveInsight's glioblastoma pipeline report depicts a robust pipeline with 150+ active companies developing therapies for glioblastoma treatment.
• Key glioblastoma companies such as Kazia Therapeutics, BPGbio, VBI Vaccines, BeyondBio, Reglagene, Diakonos Oncology, Cue Biopharma, and others are actively evaluating novel treatment approaches.
• Promising glioblastoma pipeline therapies in various stages of development include Paxalisib, BPM31510, VBI-1901, DOC1021, CUE-102, BEY1107, and others.

Request a sample and discover the recent advances in glioblastoma treatment drugs:
https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Glioblastoma?
Glioblastoma multiforme (GBM) is the most aggressive and common form of malignant primary brain tumor in adults and is classified as a World Health Organization (WHO) grade IV astrocytoma. It originates from astrocytic glial cells and is characterized by rapid proliferation, diffuse infiltration, necrosis, and extensive microvascular proliferation within the central nervous system. Despite treatment advances involving surgery, radiotherapy, and temozolomide chemotherapy, the disease continues to have a poor prognosis, with median survival generally ranging between 12 and 15 months.

Symptoms of glioblastoma commonly include persistent headaches, nausea, vomiting, seizures, neurological deficits, cognitive dysfunction, memory impairment, and personality changes depending on tumor location and progression.

Diagnosis generally relies on MRI imaging, biopsy, histopathological examination, and molecular testing for biomarkers such as IDH mutation, MGMT methylation, and EGFR amplification.

Emerging Glioblastoma Drug Profiles

Paxalisib: Kazia Therapeutics
Paxalisib is an orally administered phosphatidylinositol 3 kinase (PI3K) inhibitor being developed by Kazia Therapeutics for glioblastoma treatment. The therapy is currently being evaluated in Phase III clinical development for glioblastoma and aims to target pathways associated with tumor growth and survival.

BPM31510: BPGbio
BPM31510-IV is a drug-lipid conjugate nanodispersion containing oxidized Coenzyme Q10 (CoQ10) under clinical development for glioblastoma multiforme. The therapy works by shifting cancer metabolism from glycolysis toward mitochondrial oxidative phosphorylation, inducing oxidative stress and cancer cell death. BPM31510 is currently being investigated in a Phase II study in combination with Vitamin K1 for newly diagnosed glioblastoma patients.

Learn more about the novel and emerging glioblastoma pipeline therapies:
https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Recent Developments in the Glioblastoma Clinical Trial Landscape
• In March 2026, Diakonos Oncology announced that new clinical trial data on DOC1021 (dubodencel), a patient-derived double-loaded dendritic cell investigational therapy, would be presented at the AACR Annual Meeting and the American Academy of Neurology Annual Meeting.
• In January 2026, TransCode Therapeutics announced publication of preclinical research supporting the use of TTX-MC138 for glioblastoma multiforme treatment.
• In October 2025, BPGbio announced presentation of two posters on BPM31510 at the European Society for Medical Oncology (ESMO) Congress 2025 in collaboration with Stanford University School of Medicine and leading US cancer centers.
• In September 2025, BPGbio reported completion of enrollment in its Phase IIb trial evaluating BPM31510-IV in combination with Vitamin K1 for newly diagnosed glioblastoma multiforme patients. Topline results are anticipated in 2026.
• In March 2026, INOVIO and Akeso entered into a clinical trial collaboration and supply agreement to evaluate INO-5412 in combination with cadonilimab for glioblastoma within the INSIGhT adaptive Phase II platform trial.

Scope of the Glioblastoma Pipeline Report
• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Preclinical, Phase I, Phase II, Phase III
• Therapeutic Assessment By Route of Administration: Oral, Intravenous, Intratumoral, Intrathecal, Intranasal, Intradermal, Parenteral, and others
• Therapeutic Assessment By Molecule Type: Small molecules, Antibodies, CAR-T cell therapies, Vaccines, Gene therapies, Peptides, Oncolytic viruses, Recombinant proteins, Stem cell therapies, and others
• Key Glioblastoma Companies: Kazia Therapeutics, BPGbio, VBI Vaccines, BeyondBio, Reglagene, Diakonos Oncology, Cue Biopharma, and others
• Key Glioblastoma Pipeline Therapies: Paxalisib, BPM31510, VBI-1901, DOC1021, CUE-102, BEY1107, and others

Dive deep into rich insights for new drugs for glioblastoma treatment:
https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents
1. Glioblastoma Pipeline Report Introduction
2. Glioblastoma Pipeline Report Executive Summary
3. Glioblastoma Pipeline: Overview
4. Analytical Perspective and Commercial Assessment
5. Glioblastoma Pipeline Therapeutics
6. Late-stage Glioblastoma Products
7. Mid-stage Glioblastoma Products
8. Early-stage Glioblastoma Products
9. Glioblastoma Pipeline Therapeutics Assessment
10. Inactive Products in the Glioblastoma Pipeline
11. Collaborations Assessment (Licensing/Partnering/Funding)
12. Key Companies
13. Key Products in the Glioblastoma Pipeline
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix
For further information on the glioblastoma pipeline therapeutics, reach out:
https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. The company offers healthcare market research, pipeline intelligence, competitive benchmarking, and consulting services through its subscription-based platform PharmDelve.

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. The company offers healthcare market research, pipeline intelligence, competitive benchmarking, and consulting services through its subscription-based platform PharmDelve.

This release was published on openPR.